Pfizer Stock: Shares Rebound 4.59% After Solid Q3 Results
Pfizer's stock closed higher on Tuesday, November 11, 2025, appreciating by 4.59% to $25.51. This increase follows the publication of quarterly results that exceeded earnings expectations. The upward trend in the stock accompanies the pharmaceutical group's third-quarter figures.
Market Performance on November 11, 2025
Pfizer's stock rose by 4.59% at the close of November 11, 2025, finishing at $25.51. This increase is part of a positive trend for the American pharmaceutical group. Over the week, the stock has shown a gain of 4.98%, while the broader S&P 500 index closed up 0.36% at 6,740.28 points on the same day. This relative outperformance of Pfizer’s stock highlights particular attention from market participants. In terms of trading volume, 137.7 million shares were traded at the close of November 11, representing 2.42% of the total market capitalization of the group. This significant volume reflects marked interest in the stock. On an annual basis, Pfizer's performance remains moderate. The stock has recorded a decline of 2.78% since the start of 2025, while the S&P 500 has advanced 18.33% over the same period. This divergence shows that the pharmaceutical sector has not enjoyed the same momentum as the broader index. Nevertheless, the stock is positioned close to its highs, having reached $27.37 in October 2025 and currently trading at $25.51.
Impact of Q3 Fiscal 2025 Results
The stock's rise on November 11 can largely be attributed to the third-quarter fiscal 2025 results released on November 4. Pfizer exceeded analysts' expectations for adjusted earnings per share, recording $0.87 versus a consensus of $0.79. Revenue for the quarter was set at $16.65 billion, slightly below the expected $16.94 billion. Despite this slight disappointment in revenue, the group has strengthened its guidance for the fiscal year 2025, raising the adjusted earnings per share range to $3.00-$3.15 from $2.90-$3.10 previously. These results reflect a gradual correction of Pfizer's dependence on COVID-19 related products. COVID revenue has declined due to lower infection rates and more restrictive vaccine recommendations in the United States. In contrast, the group's non-COVID portfolio has seen operational growth of 4%. More broadly, Pfizer also benefits from an agreement announced about a month ago with the U.S. government regarding drug pricing. This voluntary agreement provides for the alignment of Pfizer's Medicaid prices with those of other developed countries and an average reduction of 50% for consumers through a dedicated government website. The group has committed to investing $70 billion in research and manufacturing in the United States, securing a three-year tariff exemption. This arrangement has been positively interpreted by the market as reducing regulatory risks weighing on the pharmaceutical sector.
Technical Analysis
Technically, the stock is trading above its 50-day moving average of $24.74, suggesting a short-term bullish trend for the stock.
